Progyny (NASDAQ:PGNY) Updates FY 2025 Earnings Guidance

Key Points

• Progyny has updated its FY 2025 earnings guidance, projecting earnings per share (EPS) between 1.700-1.780, significantly higher than the consensus estimate of 0.540.
• The company's revenue guidance for FY 2025 is set at $1.2 billion-$1.3 billion, aligning with the consensus revenue estimate.
• Progyny's stock is currently trading at $23.06, down 1.8%, and the company's market capitalization stands at $1.98 billion.

Progyny (NASDAQ:PGNY - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.700-1.780 for the period, compared to the consensus estimate of 0.540. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion. Progyny also updated its Q3 2025 guidance to EPS.

Progyny Stock Down 1.8%

PGNY traded down $0.43 during trading on Thursday, hitting $23.06. The company had a trading volume of 1,969,564 shares, compared to its average volume of 900,036. The company has a market capitalization of $1.98 billion, a PE ratio of 40.46, a PEG ratio of 2.36 and a beta of 1.32. Progyny has a one year low of $13.39 and a one year high of $26.76. The firm's 50-day moving average price is $22.30 and its 200 day moving average price is $22.16.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.33% and a return on equity of 10.90%. During the same period in the prior year, the firm posted $0.17 earnings per share. The company's revenue was up 9.5% on a year-over-year basis. Sell-side analysts forecast that Progyny will post 0.6 earnings per share for the current year.

Wall Street Analyst Weigh In

PGNY has been the topic of several analyst reports. Leerink Partnrs raised shares of Progyny from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 8th. Truist Financial boosted their price objective on shares of Progyny from $24.00 to $27.00 and gave the stock a "hold" rating in a research note on Thursday, July 17th. Wall Street Zen upgraded shares of Progyny from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Canaccord Genuity Group lowered their price target on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Finally, Leerink Partners raised Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective for the company in a research report on Tuesday, July 8th. Five analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Progyny has a consensus rating of "Moderate Buy" and a consensus target price of $24.82.

Insider Transactions at Progyny

In other Progyny news, Director Cheryl Scott sold 2,675 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the transaction, the director owned 14,112 shares in the company, valued at $311,451.84. This trade represents a 15.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Progyny

Several institutional investors and hedge funds have recently modified their holdings of PGNY. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company's stock valued at $5,630,000 after purchasing an additional 14,297 shares during the period. Amundi raised its position in shares of Progyny by 103.8% in the first quarter. Amundi now owns 11,419 shares of the company's stock valued at $264,000 after buying an additional 5,817 shares in the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Progyny by 384.8% in the first quarter. Royal Bank of Canada now owns 13,027 shares of the company's stock valued at $291,000 after buying an additional 10,340 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.